Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Antengene Acquires Global Rights to AstraZeneca Cancer Candidate

publication date: Nov 7, 2019

Antengene, a Shanghai novel drug biopharma, has in-licensed global rights to a novel cancer treatment from AstraZeneca. The company said AstraZeneca has filed an open IND application for AZD0364, a selective small molecule ERK1/2 inhibitor, in the US for multiple solid tumor cancers. ERK is a key component of the Ras-Raf-MEK-ERK (RAS/MAPK) pathway, which promotes tumor cell growth and survival. Antengene expects the candidate will be effective as a monotherapy and in combination with other of its portfolio drugs. Details of the agreement were not disclosed. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China